National Research Council of Canada

University of Ottawa

University of Massachusetts

Dennis M Whitfield

Ian C Schoenhofen

Susan M Logan

Christopher Noyce Boddy

Benjamin R Lundgren

Lakshmi Krishnan

Sanjay Ram

G Dennis Sprott

Dennis Sprott

Ian Schoenhofen

has become resistant to almost every conventional antibiotic. Described herein is the use of CMP-nonulosonate analogues to counter gonococcal complement evasion. The nonulosonate sugar is incorporated into the lipooligosaccharide of thewhich in turn reduces the serum resistance of the bacteria. This provides a novel therapeutic strategy against the global threat of multi-drug resistant gonorrhea.

therapeutic based on CMP-nonulosonate sugars

A synthetic charged glycolipid is described comprising a sulfated saccharide group covalently linked to the tree sn-1 hydroxyl group of the glycerol backbone of an archaeal core lipid via a beta linkage. The synthetic charged glycolipids include compounds of formula I wherein n is 0 or 1; R is hydrogen or hydroxyl; and Y is hydrogen or a sulfate group, at least one Y being a sulfate group; and including pharmaceutically acceptable salts thereof. The sulfated glycolipid produces stable archaeosomes at a mol % ratio of from 100:0 to 30:70 (sulfated glycolipid:uncharged glycolipid) and which induce a protective immune response, including CD8and CD4T cell responses. Archaeosomes comprising the sulfated glycolipids described have desirable adjuvant properties, particularly when mixed with uncharged glycolipid at a mol % ratio of about 50:50. 

Sulfated-glycolipids as adjuvants for vaccines

The present invention relates to the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-&#x3b2;-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-&#x3b1;-D-glucopyranose. Methods for producing the sugars are also provided.

Cell-based production of nonulosonates

has become resistant to almost every conventional antibiotic. Described herein is the use of CMP-nonulosonate analogs to counter gonococcal complement evasion. The nonulosonate sugar is incorporated into the lipooligosaccharide of thewhich in turn reduces the serum resistance of the bacteria. This provides a novel therapeutic strategy against the global threat of multi-drug resistant

[object Object]

The present invention relates to the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-&#x25a1;-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-&#x25a1;-D-glucopyranose. Methods for producing the sugars are also provided.

The present invention describes compounds of Formula I or a pharmaceutically acceptable salts or derivatives thereof. Compositions comprising compounds of Formula I are also described. The present invention further relates to a method of producing non-2-enonate compounds. 

Inhibitors of sialidase or sialidase-like enzymes

Archaeal lipid adjuvants are synthesized by chemically coupling various carbohydrates or anionic polar groups to the free hydroxyl(s) of archaeal lipid cores. Chemically stable lipid cores such as saturated archaeol and caldarchaeol are obtained from appropriate Archaea. Archaeosome lipid vesicles are formulated from the synthetic lipids selected to serve as antigen carriers that target antigen-presenting cells and promote an appropriate immune response to the antigen.

Growing community of inventors

Ottawa, Canada

Dennis M Whitfield